We are upgrading the repository! A content freeze is in effect until December 6, 2024. New submissions or changes to existing items will not be allowed during this period. All content already published will remain publicly available for searching and downloading. Updates will be posted in the Website Upgrade 2024 FAQ in the sidebar Help menu. Reach out to escholarship@umassmed.edu with any questions.

Show simple item record

dc.contributor.authorHenninger, Nils
dc.contributor.authorFisher, Marc
dc.date2022-08-11T08:09:28.000
dc.date.accessioned2022-08-23T16:31:52Z
dc.date.available2022-08-23T16:31:52Z
dc.date.issued2016-01-07
dc.date.submitted2016-05-10
dc.identifier.citationTransl Stroke Res. 2016 Jan 7. <a href="http://dx.doi.org/10.1007/s12975-015-0444-4">Link to article on publisher's site</a>
dc.identifier.issn1868-4483 (Linking)
dc.identifier.doi10.1007/s12975-015-0444-4
dc.identifier.pmid26739964
dc.identifier.urihttp://hdl.handle.net/20.500.14038/37753
dc.description<p>First author Nils Henninger is a doctoral student in the Millennium PhD Program (MPP) in the Graduate School of Biomedical Sciences (GSBS) at UMass Medical School.</p>
dc.description.abstractPharmacological and device-induced reperfusion therapies have demonstrated increasingly positive outcomes regarding both reperfusion efficacy and 90-day functional outcomes after acute ischemic stroke. However, presently, only a minority of patients are eligible for these treatments. Less than 10 % of all ischemic stroke patients receive intravenous thrombolysis in most centers and it has been projected that only approximately 7-15 % of ischemic stroke patients are eligible for acute endovascular intervention. Making these effective therapies safely available to a much larger number of patients is critical for expanding the benefits of acute ischemic stroke treatment. In this article, we summarize the key results from the clinical trials, challenges, and exciting novel opportunities to increase patient eligibility for these therapies as well as for better outcomes for stroke patients.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=26739964&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1007/s12975-015-0444-4
dc.subjectNervous System Diseases
dc.subjectNeurology
dc.titleExtending the Time Window for Endovascular and Pharmacological Reperfusion
dc.typeJournal Article
dc.source.journaltitleTranslational stroke research
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/neuro_pp/427
dc.identifier.contextkey8585879
html.description.abstract<p>Pharmacological and device-induced reperfusion therapies have demonstrated increasingly positive outcomes regarding both reperfusion efficacy and 90-day functional outcomes after acute ischemic stroke. However, presently, only a minority of patients are eligible for these treatments. Less than 10 % of all ischemic stroke patients receive intravenous thrombolysis in most centers and it has been projected that only approximately 7-15 % of ischemic stroke patients are eligible for acute endovascular intervention. Making these effective therapies safely available to a much larger number of patients is critical for expanding the benefits of acute ischemic stroke treatment. In this article, we summarize the key results from the clinical trials, challenges, and exciting novel opportunities to increase patient eligibility for these therapies as well as for better outcomes for stroke patients.</p>
dc.identifier.submissionpathneuro_pp/427
dc.contributor.departmentDepartment of Neurology


This item appears in the following Collection(s)

Show simple item record